Team Leader
Prof. Dr. Agustín Albillos
Professor of Medicine at the University of Alcalá,
Group Leader at IRYCIS
Team Staff
Dr. Laura Garcia-Bermejo
Institute Presentation
Servicio Madrileño de Salud (SERMAS) integrates every public hospital and other public health services of the Madrid Regional Health System. Hospital Universitario Ramón y Cajal (HURYC) is the public hospital contributing to DECISION. HURYC is a 1200-bed university hospital in Madrid founded in 1977 and affiliated to Universidad de Alcalá de Henares. It provides comprehensive health care in all medical and surgical specialties and has a basic research department and major research infrastructures. It has an established research institute (IRYCIS) that encompasses basic, translational, and clinical research departments, with all the required infrastructures to perform phase I to IV clinical trials, including full laboratory and imaging equipment and an Ethical Committee. It ranks first in Madrid and third in Spain in the production of biomedical research, working in partnership with more than 50 international leading centres.
The Department of Gastroenterology and Hepatology of HRYC see patients with decompensated cirrhosis and ACLF that are referred for evaluation in the liver transplantation unit, one of the largest of Spain. The conjunction of a large number of patients with advanced liver disease that come or are referred to the hospital and the sophisticated translational research facilities made the hospital and the associated research institute unique for the study of decompensated cirrhosis and acute-on-chronic liver failure (ACLF). Specifically, the Department of Gastroenterology and Hepatology has extensive experience in the management of patients with cirrhosis and ACLF, in the use of artificial liver support and in liver transplantation. More importantly, we have deep know-how in the development and use of experimental models of cirrhosis and ACLF, in the study of inflammation and immune dysfunction in the whole spectrum of human and experimental cirrhosis, in the evaluation of the gut-liver axis in experimental models of cirrhosis and in liver hemodynamics.
SERMAS will participate mainly in WP5, contributing with its leading clinical expertise in the management of decompensated cirrhosis and in the field of clinical research.